DermaSensor
DermaSensor sells a handheld device that checks suspicious skin spots for cancer risk immediately.
01What it doesDermaSensor sells a handheld device that checks suspicious skin spots for cancer risk immediately.Source-grounded · automated review · Explore ↗
Checked 2026-09-12 · Review due 2026-09-19
Read supporting source ↗combines Elastic Scattering Spectroscopy with…
02Who is involvedEvidence still neededOpen review status ↗
Supported. Document 0 says the financing included a $4 million Series B extension from institutional and strategic investors and more than $1 million raised through a community investment round on Wefunder. It does not name specific investors.
03What happenedEvidence still neededOpen review status ↗
Supported as phrased in the draft: Document 0 says DermaSensor raised more than $5 million in new financing, including a $4 million Series B extension. However, the exact target round/date are not fully verified: the document describes a Series B extension, not simply a Series B, and the provided do
04Why it mattersNew U.S. partnerships could help the device reach primary care, enterprise and federal health systems.Interpretation · Explore ↗
Checked 2026-09-12 · Review due 2026-09-19
Read supporting source ↗four new U.S. partnerships spanning…
DermaSensor · Financing Record
Explore source-linked visual explanations for DermaSensor. Unsupported claims are withheld while source review continues.
Record 12162 · Recorded date: 2026-09-12
Explore company records →